SOLICITATION NOTICE
Q -- Whole Genome Amplification.
- Notice Date
- 8/16/2011
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-110130-EB
- Archive Date
- 9/14/2011
- Point of Contact
- Erin M. Breedlove, Phone: 3014968607, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
breeerin@mail.nih.gov, cr214i@nih.gov
(breeerin@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6068, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Center for Cancer Research (CCR) plans to procure on a sole source basis with Qiagen Inc, 19300 Germantown Rd, Germantown, MD 20874 for whole Genome amplification. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The North American Industry Classification System code is 541380 and the business size standard is $12M. Period of performance is from September 1, 2011 through December 1, 2011. NCI is engaged in genomic research of pediatric cancers using genetic materials, such as genomic DNA, extracted from patient tissue samples. Patient derived genomic DNA is considered as very precious due to the limited quantity of tissue available in tissue banks. NCI's research relies heavily on high quality genomic DNA for experiments including genomic DNA sequencing and array comparative genomic hybridization (a-CGH). NCI has an inventory of nearly 1,000 genomic DNA samples from a variety of pediatric patient tumor samples and NCI is collecting additional clinical specimen through different sources. Due to the extensive number of experiments already performed and the demand for larger quantities of genomic DNA for ongoing experiments using new state of the art technologies (i.e. Next Generation Sequencing), NCI is using up the genomic DNA from many of the samples in NCI's inventory. NCI proposes to amplify and store tumor DNA samples using the DNA amplification service (REPLI-g) provided by Qiagen. The REPLI-g amplification procedure relies on multiple displacement amplification (MDA) method using Phi-29 DNA polymerase to produce 100 ug or 500 ug yields from 100ng of starting material. The use of Phi-29 DNA polymerase method avoids the shortcomings of adaptor-based PCR whole genome amplification method which is deleterious for the next-generation sequencing due to the artificially over representation of common primer sequences. This feature is critical to NCI's research such as next-generation re-sequencing. Therefore the Qiagen REPLI-g service provides the most accurate, highest quality process for amplifying genomic DNA and provides an adequate sample for NCI's ongoing and upcoming projects. Qiagen is the leading and reputable manufacturer of making DNA, RNA purification and amplification kits in the market. Qiagen is the only company providing multiple displacement amplification service using Phi-29 DNA polymerase method in United States, which is important for time constraints. The service includes strict prior and post amplification QA/QC criteria to ensure the quality of the amplified samples. NCI has used Qiagen REPLI-g service to amplify 1322 samples before. The results from the previous service have been satisfactory and we decided to continue to use their service for amplify genomic DNA of clinical samples for consistency and quality reasons. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 30, 2011. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Erin Breedlove, Contract Specialist at breeerin@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-110130-EB on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-110130-EB/listing.html)
- Record
- SN02537220-W 20110818/110817000649-d1b69f07b8b8505649c51f22af520835 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |